Molecular Modeling Market Research Report Information By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End User (Pharmaceutical & Biotechnology Companies, Research & Academic Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

LIST OF CONTENTS

1 EXECUTIVE SUMMARY 15

2 MARKET INTRODUCTION 16

2.1 DEFINITION 16

2.2 SCOPE OF THE STUDY 16

2.3 RESEARCH OBJECTIVE 16

2.4 MARKET STRUCTURE 16

2.5 ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY 18

3.1 DATA MINING 18

3.2 SECONDARY RESEARCH 19

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 21

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.6.1 BOTTOM-UP APPROACH 23

3.6.2 TOP-DOWN APPROACH 23

3.7 DATA TRIANGULATION 24

3.8 VALIDATION 24

4 MARKET DYNAMICS 25

4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISEASES LEADING TO DRUG DEVELOPMENT 26

4.2.2 TECHNOLOGICAL ADVANCEMENTS IN DRUG DESIGN 26

4.2.3 INCREASING INVESTMENTS IN RESEARCH & DEVELOPMENT BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 26

4.3 RESTRAINTS 27

4.3.1 HIGH COST OF MOLECULAR MODELLING SOFTWARE 27

4.3.2 LACK OF SKILLED HEALTHCARE IT PROFESSIONALS IN LOW AND MIDDLE-INCOME ECONOMIES 27

4.4 OPPORTUNITIES 28

4.4.1 INTRODUCTION OF MOLECULAR MODELLING SOFTWARE AND SERVICES IN DEVELOPING ECONOMIES 28

5 MARKET FACTOR ANALYSIS 29

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 INPUTS 30

5.1.2 SOFTWARE DEVELOPMENT PROCESSES 30

5.1.3 OUTPUT 30

5.1.4 MARKETING AND DISTRIBUTION 30

5.1.5 POST-SELLING SERVICES 30

5.2 PORTER’S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 32

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 BARGAINING POWER OF BUYERS 32

5.2.4 THREAT OF SUBSTITUTES 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 COVID-19 IMPACT 33

5.3.1 OVERVIEW 33

5.3.2 IMPACT ON MARKET GROWTH 33

5.3.3 IMPACT ON THE DRUG DESIGN PROCESS 33

5.3.4 IMPACT ON MARKET GROWTH 33

6 GLOBAL MOLECULAR MODELLING MARKET BY PRODUCT 34

6.1 INTRODUCTION 34

6.2 SOFTWARE 35

6.3 SERVICES 35

7 GLOBAL: MOLECULAR MODELLING MARKET BY APPLICATION 36

7.1 INTRODUCTION 36

7.2 DRUG DEVELOPMENT 37

7.3 DRUG DISCOVERY 37

7.4 OTHERS 39

8 GLOBAL MOLECULAR MODELLING MARKET BY END USER 40

8.1 INTRODUCTION 40

8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 41

8.3 RESEARCH & ACADEMIC CENTERS 41

8.4 OTHERS 42

9 GLOBAL MOLECULAR MODELLING MARKET, BY REGION 43

9.1 INTRODUCTION 43

9.2 AMERICAS 44

9.2.1 NORTH AMERICA 47

9.2.1.1 US 49

9.2.1.2 CANADA 50

9.2.2 SOUTH AMERICA 51

9.3 EUROPE 52

9.3.1 WESTERN EUROPE 54

9.3.1.1 GERMANY 56

9.3.1.2 FRANCE 57

9.3.1.3 UK 58

9.3.1.4 ITALY 59

9.3.1.5 SPAIN 60

9.3.1.6 REST OF WESTERN EUROPE 61

9.3.2 EASTERN EUROPE 62

9.4 ASIA-PACIFIC 64

9.4.1 CHINA 66

9.4.2 INDIA 67

9.4.3 JAPAN 68

9.4.4 AUSTRALIA 69

9.4.5 SOUTH KOREA 70

9.4.6 REST OF ASIA-PACIFIC 71

9.5 MIDDLE EAST & AFRICA 72

9.5.1 MIDDLE EAST 74

9.5.2 AFRICA 75

10 COMPETITIVE LANDSCAPE 76

10.1 OVERVIEW 76

10.2 COMPETITIVE BENCHMARKING 77

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MOLECULAR MODELING MARKET 78

10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE

GLOBAL MOLECULAR MODELING MARKET 79

10.5 KEY DEVELOPMENT ANALYSIS 79

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 80

10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 80

10.6.2 MERGER/ACQUISITION 81

10.6.3 PARTNERSHIP/AGREEMENT/COLLABORATION 81

10.6.4 EXPANSION/INVESTMENT 82

11 COMPANY PROFILES 83

11.1 SIMULATIONS PLUS, INC. 83

11.1.1 COMPANY OVERVIEW 83

11.1.2 FINANCIAL OVERVIEW 84

11.1.3 PRODUCTS/SERVICES OFFERED 85

11.1.4 KEY DEVELOPMENTS 85

11.1.5 SWOT ANALYSIS 86

11.1.6 KEY STRATEGY 86

11.2 CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE 87

11.2.1 COMPANY OVERVIEW 87

11.2.2 FINANCIAL OVERVIEW 87

11.2.3 PRODUCTS/SERVICES OFFERED 87

11.2.4 KEY DEVELOPMENTS 87

11.2.5 SWOT ANALYSIS 88

11.2.6 KEY STRATEGY 88

11.3 OPTIBRIUM 89

11.3.1 COMPANY OVERVIEW 89

11.3.2 FINANCIAL OVERVIEW 89

11.3.3 PRODUCTS/SERVICES OFFERING 89

11.3.4 KEY DEVELOPMENTS 89

11.3.5 SWOT ANALYSIS 90

11.3.6 KEY STRATEGY 90

11.4 CRESSET 91

11.4.1 COMPANY OVERVIEW 91

11.4.2 FINANCIAL OVERVIEW 91

11.4.3 PRODUCTS/SERVICES OFFERING 91

11.4.4 KEY DEVELOPMENTS 92

11.4.5 SWOT ANALYSIS 93

11.4.6 KEY STRATEGY 93

11.5 BIOSOLVEIT GMBH 94

11.5.1 COMPANY OVERVIEW 94

11.5.2 FINANCIAL OVERVIEW 94

11.5.3 PRODUCTS/SERVICES OFFERING 94

11.5.4 KEY DEVELOPMENTS 95

11.5.5 SWOT ANALYSIS 95

11.5.6 KEY STRATEGY 96

11.6 OPENEYE SCIENTIFIC SOFTWARE 97

11.6.1 COMPANY OVERVIEW 97

11.6.2 FINANCIAL OVERVIEW 97

11.6.3 PRODUCTS OFFERING 97

11.6.4 KEY DEVELOPMENTS 98

11.6.5 SWOT ANALYSIS 98

11.6.6 KEY STRATEGY 99

11.7 CHEMICAL COMPUTING GROUP 100

11.7.1 COMPANY OVERVIEW 100

11.7.2 FINANCIAL OVERVIEW 100

11.7.3 PRODUCTS OFFERING 100

11.7.4 KEY DEVELOPMENTS 100

11.7.5 SWOT ANALYSIS 101

11.7.6 KEY STRATEGY 101

11.8 ACELLERA LTD 102

11.8.1 COMPANY OVERVIEW 102

11.8.2 FINANCIAL OVERVIEW 102

11.8.3 PRODUCTS OFFERING 102

11.8.4 KEY DEVELOPMENTS 102

11.8.5 SWOT ANALYSIS 103

11.8.6 KEY STRATEGY 103

11.9 DASSAULT SYSTÈMES 104

11.9.1 COMPANY OVERVIEW 104

11.9.2 FINANCIAL OVERVIEW 105

11.9.3 PRODUCTS/SERVICES OFFERED 106

11.9.4 KEY DEVELOPMENTS 106

11.9.5 SWOT ANALYSIS 106

11.9.6 KEY STRATEGIES 107

11.10 SCHRÖDINGER, LLC 108

11.10.1 COMPANY OVERVIEW 108

11.10.2 FINANCIAL OVERVIEW 108

11.10.3 PRODUCTS/SERVICES OFFERED 108

11.10.4 KEY DEVELOPMENTS 108

11.10.5 SWOT ANALYSIS 109

11.10.6 KEY STRATEGIES 109

11.11 CERTARA L.P. 110

11.11.1 COMPANY OVERVIEW 110

11.11.2 FINANCIAL OVERVIEW 110

11.11.3 PRODUCTS/SERVICES OFFERED 110

11.11.4 KEY DEVELOPMENTS 110

11.11.5 SWOT ANALYSIS 111

11.11.6 KEY STRATEGIES 111

12 APPENDIX 112

12.1 REFERENCES 112

12.2 RELATED REPORTS 112

TABLE CONTENTS

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 17

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20

TABLE 3 GLOBAL: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 34

TABLE 4 GLOBAL: MOLECULAR MODELLING MARKET, BY SOFTWARE, BY REGION, 2022–2030 (USD MILLION) 35

TABLE 5 GLOBAL: MOLECULAR MODELLING MARKET, BY SERVICES, BY REGION, 2022–2030 (USD MILLION) 35

TABLE 6 GLOBAL: MOLECULAR MODELLING MARKET, BY APPLICATION, 2020 & 2030 (USD MILLION) 36

TABLE 7 GLOBAL: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 36

TABLE 8 GLOBAL: MOLECULAR MODELLING MARKET, BY DRUG DEVELOPMENT, BY REGION, 2022–2030 (USD MILLION) 37

TABLE 9 GLOBAL: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY, BY REGION, 2022–2030 (USD MILLION) 37

TABLE 10 GLOBAL: MOLECULAR MODELLING MARKET, FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 38

TABLE 11 GLOBAL: MOLECULAR MODELLING MARKET, FOR DIRECT DRUG DESIGN, BY REGION, 2022–2030 (USD MILLION) 38

TABLE 12 GLOBAL: MOLECULAR MODELLING MARKET, FOR INDIRECT DRUG DESIGN, BY REGION, 2022–2030 (USD MILLION) 38

TABLE 13 GLOBAL: MOLECULAR MODELLING MARKET, FOR MOLECULAR MIMICRY, BY REGION, 2022–2030 (USD MILLION) 39

TABLE 14 GLOBAL: MOLECULAR MODELLING MARKET, BY OTHERS, BY REGION, 2022–2030 (USD MILLION) 39

TABLE 15 GLOBAL: MOLECULAR MODELLING MARKET, BY END USER, 2020 & 2030 (USD MILLION) 40

TABLE 16 GLOBAL: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 40

TABLE 17 GLOBAL: MOLECULAR MODELLING MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,

BY REGION, 2022–2030 (USD MILLION) 41

TABLE 18 GLOBAL: MOLECULAR MODELLING MARKET, BY RESEARCH & ACADEMIC CENTERS, BY REGION,

2022–2030 (USD MILLION) 41

TABLE 19 GLOBAL: MOLECULAR MODELLING MARKET, BY OTHERS, BY REGION, 2022–2030 (USD MILLION) 42

TABLE 20 GLOBAL: MOLECULAR MODELLING MARKET, BY REGION 2020 & 2030 (USD MILLION) 43

TABLE 21 GLOBAL: MOLECULAR MODELLING MARKET, BY REGION 2022–2030 (USD MILLION) 43

TABLE 22 GLOBAL: MOLECULAR MODELLING MARKET SHARE, BY REGION, 2020 (%) 44

TABLE 23 AMERICAS: MOLECULAR MODELLING MARKET, BY REGION, 2022–2030 (USD MILLION) 44

TABLE 24 AMERICAS: MOLECULAR MODELLING MARKET SHARE, BY REGION 2020 (%) 45

TABLE 25 AMERICAS: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 45

TABLE 26 AMERICAS: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 45

TABLE 27 AMERICAS: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 46

TABLE 28 AMERICAS: MOLECULAR MODELLING MARKET, BY END USER , 2022–2030 (USD MILLION) 46

TABLE 29 NORTH AMERICA: MOLECULAR MODELLING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 47

TABLE 30 NORTH AMERICA: MOLECULAR MODELLING MARKET SHARE, BY COUNTRY, 2020 (%) 47

TABLE 31 NORTH AMERICA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 47

TABLE 32 NORTH AMERICA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 48

TABLE 33 NORTH AMERICA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 48

TABLE 34 NORTH AMERICA: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 48

TABLE 35 US: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 49

TABLE 36 US: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 49

TABLE 37 US: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 49

TABLE 38 US: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 49

TABLE 39 CANADA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 50

TABLE 40 CANADA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 50

TABLE 41 CANADA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 50

TABLE 42 CANADA: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 50

TABLE 43 SOUTH AMERICA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 51

TABLE 44 SOUTH AMERICA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 51

TABLE 45 SOUTH AMERICA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 51

TABLE 46 SOUTH AMERICA: MOLECULAR MODELLING MARKET, BY END USER , 2022–2030 (USD MILLION) 51

TABLE 47 EUROPE: MOLECULAR MODELLING MARKET, BY REGION, 2022–2030 (USD MILLION) 52

TABLE 48 EUROPE: MOLECULAR MODELLING MARKET SHARE, BY REGION 2020 (%) 52

TABLE 49 EUROPE: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 53

TABLE 50 EUROPE: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 53

TABLE 51 EUROPE: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 53

TABLE 52 EUROPE: MOLECULAR MODELLING MARKET, BY END USER , 2023-2032 (USD MILLION) 53

TABLE 53 WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 54

TABLE 54 WESTERN EUROPE: MOLECULAR MODELLING MARKET SHARE, BY COUNTRY, 2020 (%) 54

TABLE 55 WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 54

TABLE 56 WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 55

TABLE 57 WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 55

TABLE 58 WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY END USER , 2022–2030 (USD MILLION) 55

TABLE 59 GERMANY: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 56

TABLE 60 GERMANY: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 56

TABLE 61 GERMANY: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 56

TABLE 62 GERMANY: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 56

TABLE 63 FRANCE: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 57

TABLE 64 FRANCE: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 57

TABLE 65 FRANCE: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 57

TABLE 66 FRANCE: MOLECULAR MODELLING MARKET, BY END USER , 2022–2030 (USD MILLION) 57

TABLE 67 UK MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 58

TABLE 68 UK MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 58

TABLE 69 UK: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 58

TABLE 70 UK: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 58

TABLE 71 ITALY: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 59

TABLE 72 ITALY: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 59

TABLE 73 ITALY: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 59

TABLE 74 ITALY: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 59

TABLE 75 SPAIN: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 60

TABLE 76 SPAIN: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 60

TABLE 77 SPAIN: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 60

TABLE 78 SPAIN: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 60

TABLE 79 REST OF WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 61

TABLE 80 REST OF WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 61

TABLE 81 REST OF WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 61

TABLE 82 REST OF WESTERN EUROPE: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 62

TABLE 83 EASTERN EUROPE: MOLECULAR MODELLING MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 62

TABLE 84 EASTERN EUROPE: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 62

TABLE 85 EASTERN EUROPE: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2022–2030 (USD MILLION) 63

TABLE 86 EASTERN EUROPE: MOLECULAR MODELLING MARKET, BY END USER, 2022–2030 (USD MILLION) 63

TABLE 87 ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 64

TABLE 88 ASIA-PACIFIC: MOLECULAR MODELLING MARKET SHARE, BY COUNTRY 2020 (%) 64

TABLE 89 ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 65

TABLE 90 ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 65

TABLE 91 ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 65

TABLE 92 ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 65

TABLE 93 CHINA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 66

TABLE 94 CHINA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 66

TABLE 95 CHINA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 66

TABLE 96 CHINA: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 66

TABLE 97 INDIA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 67

TABLE 98 INDIA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 67

TABLE 99 INDIA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 67

TABLE 100 INDIA: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 67

TABLE 101 JAPAN: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 68

TABLE 102 JAPAN: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 68

TABLE 103 JAPAN: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 68

TABLE 104 JAPAN: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 68

TABLE 105 AUSTRALIA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 69

TABLE 106 AUSTRALIA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 69

TABLE 107 AUSTRALIA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 69

TABLE 108 AUSTRALIA: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 69

TABLE 109 SOUTH KOREA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 70

TABLE 110 SOUTH KOREA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 70

TABLE 111 SOUTH KOREA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 70

TABLE 112 SOUTH KOREA: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 70

TABLE 113 REST OF ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 71

TABLE 114 REST OF ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 71

TABLE 115 REST OF ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 71

TABLE 116 REST OF ASIA-PACIFIC: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 71

TABLE 117 MIDDLE EAST & AFRICA: MOLECULAR MODELLING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 72

TABLE 118 MIDDLE EAST & AFRICA: MOLECULAR MODELLING MARKET SHARE, BY COUNTRY 2020 (%) 72

TABLE 119 MIDDLE EAST & AFRICA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 73

TABLE 120 MIDDLE EAST & AFRICA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2022 – 2030 (USD MILLION) 73

TABLE 121 MIDDLE EAST & AFRICA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 73

TABLE 122 MIDDLE EAST & AFRICA: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 73

TABLE 123 MIDDLE EAST: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 74

TABLE 124 MIDDLE EAST: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 74

TABLE 125 MIDDLE EAST: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 74

TABLE 126 MIDDLE EAST: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 74

TABLE 127 AFRICA: MOLECULAR MODELLING MARKET, BY PRODUCT, 2023-2032 (USD MILLION) 75

TABLE 128 AFRICA: MOLECULAR MODELLING MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 75

TABLE 129 AFRICA: MOLECULAR MODELLING MARKET, BY DRUG DISCOVERY TYPE, 2023-2032 (USD MILLION) 75

TABLE 130 AFRICA: MOLECULAR MODELLING MARKET, BY END USER, 2023-2032 (USD MILLION) 75

TABLE 131 MAJOR MANUFACTURERS IN THE GLOBAL MOLECULAR MODELING MARKET 76

TABLE 132 MOST ACTIVE PLAYER IN THE GLOBAL MOLECULAR MODELING MARKET 79

TABLE 133 PRODUCT LAUNCH/PRODUCT APPROVAL 80

TABLE 134 MERGER/ACQUISITION 81

TABLE 135 PARTNERSHIP/AGREEMENT/COLLABORATION 81

TABLE 136 EXPANSION/INVESTMENT 82

TABLE 137 SIMULATIONS PLUS, INC.: PRODUCTS/SERVICES OFFERED 85

TABLE 138 SIMULATIONS PLUS, INC.: KEY DEVELOPMENTS 85

TABLE 139 SIMULATIONS PLUS, INC.: PRODUCTS/SERVICES OFFERING 87

TABLE 140 SIMULATIONS PLUS, INC.: KEY DEVELOPMENTS 87

TABLE 141 OPTIBRIUM: PRODUCTS/SERVICES OFFERING 89

TABLE 142 OPTIBRIUM: KEY DEVELOPMENTS 89

TABLE 143 CRESSET: PRODUCTS/SERVICES OFFERING 91

TABLE 144 CRESSET: KEY DEVELOPMENTS 92

TABLE 145 BIOSOLVEIT GMBH: PRODUCTS/SERVICES OFFERING 94

TABLE 146 BIOSOLVEIT GMBH: KEY DEVELOPMENTS OFFERING 95

TABLE 147 OPENEYE SCIENTIFIC SOFTWARE: PRODUCTS/SERVICES OFFERING 97

TABLE 148 OPENEYE SCIENTIFIC SOFTWARE: KEY DEVELOPMENTS OFFERING 98

TABLE 149 CHEMICAL COMPUTING GROUP: PRODUCTS/SERVICES OFFERING 100

TABLE 150 ACELLERA LTD: PRODUCTS/SERVICES OFFERING 102

TABLE 151 ACELLERA LTD: KEY DEVELOPMENTS 102

TABLE 152 DASSAULT SYSTEMES: PRODUCTS/SERVICES OFFERED 106

TABLE 153 SCHRÖDINGER, LLC: PRODUCTS/SERVICES OFFERED 108

TABLE 154 CERTARA LP: PRODUCTS/SERVICES OFFERED 110

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 15

FIGURE 2 MOLECULAR MODELLING MARKET STRUCTURE 16

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22

FIGURE 4 MARKET DYNAMICS: MOLECULAR MODELLING MARKET 25

FIGURE 5 DRIVERS: IMPACT ANALYSIS 27

FIGURE 6 RESTRAINTS: IMPACT ANALYSIS 28

FIGURE 7 VALUE CHAIN: MOLECULAR MODELING MARKET 29

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: MOLECULAR MODELING MARKET 31

FIGURE 9 GLOBAL MOLECULAR MODELLING MARKET, BY PRODUCT, 2020 & 2030 (USD MILLION) 34

FIGURE 10 BENCHMARKING OF MAJOR COMPETITORS 77

FIGURE 11 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MOLECULAR MODELING MARKET 78

FIGURE 12 GLOBAL MOLECULAR MODELLING MARKET: COMPETITIVE LANDSCAPE 79

FIGURE 13 SIMULATIONS PLUS, INC.: FINANCIAL OVERVIEW SNAPSHOT 84

FIGURE 14 SIMULATIONS PLUS, INC.: SWOT ANALYSIS 86

FIGURE 15 CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE: SWOT ANALYSIS 88

FIGURE 16 OPTIBRIUM: SWOT ANALYSIS 90

FIGURE 17 CRESSET: SWOT ANALYSIS 93

FIGURE 18 BIOSOLVEIT GMBH: SWOT ANALYSIS 95

FIGURE 19 OPENEYE SCIENTIFIC SOFTWARE: SWOT ANALYSIS 98

FIGURE 20 CHEMICAL COMPUTING GROUP: SWOT ANALYSIS 101

FIGURE 21 ACELLERA LTD: SWOT ANALYSIS 103

FIGURE 22 DASSAULT SYSTÈMES: SWOT ANALYSIS 105

FIGURE 23 DASSAULT SYSTEMES: SWOT ANALYSIS 106

FIGURE 24 SCHRÖDINGER, LLC: SWOT ANALYSIS 109

FIGURE 25 CERTARA LP: SWOT ANALYSIS 111